JPWO2018009625A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018009625A5 JPWO2018009625A5 JP2019500399A JP2019500399A JPWO2018009625A5 JP WO2018009625 A5 JPWO2018009625 A5 JP WO2018009625A5 JP 2019500399 A JP2019500399 A JP 2019500399A JP 2019500399 A JP2019500399 A JP 2019500399A JP WO2018009625 A5 JPWO2018009625 A5 JP WO2018009625A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently
- independently selected
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 141
- 229910052799 carbon Inorganic materials 0.000 claims description 79
- 125000000623 heterocyclic group Chemical group 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 3
- 125000005418 aryl aryl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 3
- -1 4- (1H-pyrazole-4-yl) phenyl Chemical group 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- GDGXLYITRDZQAV-UHFFFAOYSA-N N1C2=C(CC31CCN(C3=O)C1=CC=C(C3=CNN=C3)C=C1)C=C(F)C=C2 Chemical compound N1C2=C(CC31CCN(C3=O)C1=CC=C(C3=CNN=C3)C=C1)C=C(F)C=C2 GDGXLYITRDZQAV-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- KUVFBDVJUBDKEF-UHFFFAOYSA-N C(C1CN(C(=O)C21CC1=CC=CC=C1N2)C1=CC=C(C=C1)C=1C=NNC=1)O Chemical compound C(C1CN(C(=O)C21CC1=CC=CC=C1N2)C1=CC=C(C=C1)C=1C=NNC=1)O KUVFBDVJUBDKEF-UHFFFAOYSA-N 0.000 claims 1
- XESYGOKEGVLFMK-UHFFFAOYSA-N C(COC1=CC=C2C(NC3(C2)CCN(C3=O)C2=CC=C(C=3C=NNC=3)C=C2)=C1)(C)(O)C Chemical compound C(COC1=CC=C2C(NC3(C2)CCN(C3=O)C2=CC=C(C=3C=NNC=3)C=C2)=C1)(C)(O)C XESYGOKEGVLFMK-UHFFFAOYSA-N 0.000 claims 1
- YWBFHVWUZQRCIP-UHFFFAOYSA-N C1(COC2=CC=3NC4(CC=3C=C2)CCN(C4=O)C2=CC=C(C=C2)C=2C=NNC=2)CC1 Chemical compound C1(COC2=CC=3NC4(CC=3C=C2)CCN(C4=O)C2=CC=C(C=C2)C=2C=NNC=2)CC1 YWBFHVWUZQRCIP-UHFFFAOYSA-N 0.000 claims 1
- UFIXUBXNBHETDF-UHFFFAOYSA-N C12(CCN(C1=O)C1=CC=C(C=3C=NNC=3)C=C1)CC1=CC=C(F)C=C1C2 Chemical compound C12(CCN(C1=O)C1=CC=C(C=3C=NNC=3)C=C1)CC1=CC=C(F)C=C1C2 UFIXUBXNBHETDF-UHFFFAOYSA-N 0.000 claims 1
- BCKCDMOENWEOTR-UHFFFAOYSA-N C1=2CC3(CCN(C3=O)C3=CC=C(C(OC)=C3)C=3C=NNC=3)CC1=CC=CC=2 Chemical compound C1=2CC3(CCN(C3=O)C3=CC=C(C(OC)=C3)C=3C=NNC=3)CC1=CC=CC=2 BCKCDMOENWEOTR-UHFFFAOYSA-N 0.000 claims 1
- PXBNCAPNSJKORP-UHFFFAOYSA-N C1=2CC3(CCN(C3=O)C3=CC=C(C=4C=NNC=4)C=C3)CC1=CC=C(OC)C=2 Chemical compound C1=2CC3(CCN(C3=O)C3=CC=C(C=4C=NNC=4)C=C3)CC1=CC=C(OC)C=2 PXBNCAPNSJKORP-UHFFFAOYSA-N 0.000 claims 1
- KXFCSULEXHNDMS-UHFFFAOYSA-N C1=2CC3(CCN(C3=O)C3=NC(=C(C=4C=NNC=4)C=C3)OC)CC1=CC=CC=2 Chemical compound C1=2CC3(CCN(C3=O)C3=NC(=C(C=4C=NNC=4)C=C3)OC)CC1=CC=CC=2 KXFCSULEXHNDMS-UHFFFAOYSA-N 0.000 claims 1
- QHGXHGGUNONBMJ-UHFFFAOYSA-N C1=2NC3(=C(=O)N(CC3)C3=NC=C(N=C3)C=3C=NNC=3)CC1=CC=CC=2 Chemical compound C1=2NC3(=C(=O)N(CC3)C3=NC=C(N=C3)C=3C=NNC=3)CC1=CC=CC=2 QHGXHGGUNONBMJ-UHFFFAOYSA-N 0.000 claims 1
- RMVQSTDAQPRZSX-UHFFFAOYSA-N C1=2NC3(CC1=C(F)C=C(OC)C=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 Chemical compound C1=2NC3(CC1=C(F)C=C(OC)C=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 RMVQSTDAQPRZSX-UHFFFAOYSA-N 0.000 claims 1
- UDJPKVYRYNQJQV-UHFFFAOYSA-N C1=2NC3(CC1=CC=C(OC)C=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 Chemical compound C1=2NC3(CC1=CC=C(OC)C=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 UDJPKVYRYNQJQV-UHFFFAOYSA-N 0.000 claims 1
- IKLPCFUQVDBMBF-UHFFFAOYSA-N C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C(OC)=C1)C=1C=NNC=1 Chemical compound C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C(OC)=C1)C=1C=NNC=1 IKLPCFUQVDBMBF-UHFFFAOYSA-N 0.000 claims 1
- MHRHCSNHLAHXPI-UHFFFAOYSA-N C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C2=CC=NC=C2)C=C1 Chemical compound C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C2=CC=NC=C2)C=C1 MHRHCSNHLAHXPI-UHFFFAOYSA-N 0.000 claims 1
- GVRNNYOHGGGEEX-UHFFFAOYSA-N C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C=C1)C1=CC=2C=NNC=2C=C1 Chemical compound C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C=C1)C1=CC=2C=NNC=2C=C1 GVRNNYOHGGGEEX-UHFFFAOYSA-N 0.000 claims 1
- RJXLYIPFCSEPIV-UHFFFAOYSA-N C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=NC(=C(C2=CNN=C2)C=C1)OC Chemical compound C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=NC(=C(C2=CNN=C2)C=C1)OC RJXLYIPFCSEPIV-UHFFFAOYSA-N 0.000 claims 1
- MEFGTSSAPBMNDT-UHFFFAOYSA-N C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=NC=C(C=2C=NNC=2)C=C1 Chemical compound C1=2NC3(CC1=CC=CC=2)CCN(C3=O)C1=NC=C(C=2C=NNC=2)C=C1 MEFGTSSAPBMNDT-UHFFFAOYSA-N 0.000 claims 1
- RSNXWZHLOZFELL-UHFFFAOYSA-N C1=2NC3(CCN(C3=O)C3=CC=C(C=C3)C3=CNN=C3)CC1=CC(OC)=CC=2 Chemical compound C1=2NC3(CCN(C3=O)C3=CC=C(C=C3)C3=CNN=C3)CC1=CC(OC)=CC=2 RSNXWZHLOZFELL-UHFFFAOYSA-N 0.000 claims 1
- GFAUBMISBILPCV-UHFFFAOYSA-N C1=2OC3(CC1=CC(OC)=CC=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 Chemical compound C1=2OC3(CC1=CC(OC)=CC=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 GFAUBMISBILPCV-UHFFFAOYSA-N 0.000 claims 1
- SZLPEOPUOVBLJM-UHFFFAOYSA-N C1=2OC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 Chemical compound C1=2OC3(CC1=CC=CC=2)CCN(C3=O)C1=CC=C(C=2C=NNC=2)C=C1 SZLPEOPUOVBLJM-UHFFFAOYSA-N 0.000 claims 1
- YKYJINBCIQDXOB-UHFFFAOYSA-N C1C2(C(=O)N(C1)C1=CC=C(C=3C=NNC=3)C=C1)CCC1=CC=CC=C1O2 Chemical compound C1C2(C(=O)N(C1)C1=CC=C(C=3C=NNC=3)C=C1)CCC1=CC=CC=C1O2 YKYJINBCIQDXOB-UHFFFAOYSA-N 0.000 claims 1
- VSVFGXXQZGDKOC-UHFFFAOYSA-N COC1=C(C=CC(=N1)N1CCC2(CC3=CC=C(F)C=C3C2)C1=O)C1=CNN=C1 Chemical compound COC1=C(C=CC(=N1)N1CCC2(CC3=CC=C(F)C=C3C2)C1=O)C1=CNN=C1 VSVFGXXQZGDKOC-UHFFFAOYSA-N 0.000 claims 1
- CZUKRUABVSLHGN-UHFFFAOYSA-N COC=1C=C2CC3(C(N(CC3)C3=NC(=C(C=C3)C=3C=NNC=3)OC)=O)CC2=CC=1 Chemical compound COC=1C=C2CC3(C(N(CC3)C3=NC(=C(C=C3)C=3C=NNC=3)OC)=O)CC2=CC=1 CZUKRUABVSLHGN-UHFFFAOYSA-N 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- USKLRJZVISLPLA-UHFFFAOYSA-N N1(C2=C(CC31CCN(C3=O)C1=CC=C(C=C1)C=1C=NNC=1)C=CC(OC)=C2)C Chemical compound N1(C2=C(CC31CCN(C3=O)C1=CC=C(C=C1)C=1C=NNC=1)C=CC(OC)=C2)C USKLRJZVISLPLA-UHFFFAOYSA-N 0.000 claims 1
- YWXBSRRUYFCTFK-UHFFFAOYSA-N N1(CCC2(C1=O)CC1=CC=CC=C1C2)C1=CC=C(C2=CNN=C2)C=C1 Chemical compound N1(CCC2(C1=O)CC1=CC=CC=C1C2)C1=CC=C(C2=CNN=C2)C=C1 YWXBSRRUYFCTFK-UHFFFAOYSA-N 0.000 claims 1
- AEONZEOWPZGQPC-UHFFFAOYSA-N N1=CC(=CN1)C1=CC=C(N2C(=O)C3(CC2)C(C)(C)C2=CC=CC=C2N3)C=C1 Chemical compound N1=CC(=CN1)C1=CC=C(N2C(=O)C3(CC2)C(C)(C)C2=CC=CC=C2N3)C=C1 AEONZEOWPZGQPC-UHFFFAOYSA-N 0.000 claims 1
- BVXVOSBBRKWXTM-UHFFFAOYSA-N N1C2=C(CC31CCN(C3=O)C1=CC=C(C=C1)C=1C=NNC=1)C=CC(O)=C2 Chemical compound N1C2=C(CC31CCN(C3=O)C1=CC=C(C=C1)C=1C=NNC=1)C=CC(O)=C2 BVXVOSBBRKWXTM-UHFFFAOYSA-N 0.000 claims 1
- WYMPUSJGORYQKU-UHFFFAOYSA-N N1C2=C(CCC31CCN(C3=O)C1=CC=C(C=3C=NNC=3)C=C1)C=CC=C2 Chemical compound N1C2=C(CCC31CCN(C3=O)C1=CC=C(C=3C=NNC=3)C=C1)C=CC=C2 WYMPUSJGORYQKU-UHFFFAOYSA-N 0.000 claims 1
- VQFNTTVWRYLUML-UHFFFAOYSA-N N1N=CC(=C1)C1=CC=C(C=C1)N1C(C2(C(C1)CN)NC1=CC=CC=C1C2)=O Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(C2(C(C1)CN)NC1=CC=CC=C1C2)=O VQFNTTVWRYLUML-UHFFFAOYSA-N 0.000 claims 1
- VDUBYHAYWDQMSL-UHFFFAOYSA-N N1N=CC(=C1)C1=CC=C(C=C1)N1C(C2(CC1)NC1=CC=CC(=C1C2)C)=O Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(C2(CC1)NC1=CC=CC(=C1C2)C)=O VDUBYHAYWDQMSL-UHFFFAOYSA-N 0.000 claims 1
- NZBBDMMHADSGAF-UHFFFAOYSA-N N1N=CC(=C1)C1=CC=C(C=C1)N1C(C2(CC1)NC1=CC=CC=C1C2)=O Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(C2(CC1)NC1=CC=CC=C1C2)=O NZBBDMMHADSGAF-UHFFFAOYSA-N 0.000 claims 1
- KUVFBDVJUBDKEF-FBLFFUNLSA-N N1N=CC(=C1)C1=CC=C(C=C1)N1C([C@@]2(C(C1)CO)NC1=CC=CC=C1C2)=O Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C([C@@]2(C(C1)CO)NC1=CC=CC=C1C2)=O KUVFBDVJUBDKEF-FBLFFUNLSA-N 0.000 claims 1
- KUVFBDVJUBDKEF-LFABVHOISA-N N1N=CC(=C1)C1=CC=C(C=C1)N1C([C@]2(C(C1)CO)NC1=CC=CC=C1C2)=O Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C([C@]2(C(C1)CO)NC1=CC=CC=C1C2)=O KUVFBDVJUBDKEF-LFABVHOISA-N 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- KCYPZRNQRHBHRS-UHFFFAOYSA-N O1C2=C(CC31CCN(C3=O)C1=CC=C(C3=CC=NC=C3)C=C1)C=CC=C2 Chemical compound O1C2=C(CC31CCN(C3=O)C1=CC=C(C3=CC=NC=C3)C=C1)C=CC=C2 KCYPZRNQRHBHRS-UHFFFAOYSA-N 0.000 claims 1
- 206010034636 Peripheral vascular disease Diseases 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 201000001084 cerebrovascular disease Diseases 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001613 neoplastic Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 1
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 1
- 200000000009 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662359354P | 2016-07-07 | 2016-07-07 | |
US62/359,354 | 2016-07-07 | ||
PCT/US2017/040850 WO2018009625A1 (en) | 2016-07-07 | 2017-07-06 | Spirolactams as inhibitors of rock |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2019520398A JP2019520398A (ja) | 2019-07-18 |
JP2019520398A5 JP2019520398A5 (pt) | 2020-08-13 |
JPWO2018009625A5 true JPWO2018009625A5 (pt) | 2022-03-15 |
JP7113810B2 JP7113810B2 (ja) | 2022-08-05 |
Family
ID=59351143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019500399A Active JP7113810B2 (ja) | 2016-07-07 | 2017-07-06 | Rock阻害剤としてのスピロラクタム |
Country Status (7)
Country | Link |
---|---|
US (1) | US10696674B2 (pt) |
EP (1) | EP3481817B1 (pt) |
JP (1) | JP7113810B2 (pt) |
KR (1) | KR102491994B1 (pt) |
CN (1) | CN109689639B (pt) |
ES (1) | ES2821877T3 (pt) |
WO (1) | WO2018009625A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
CN109153663B (zh) | 2016-05-27 | 2021-08-13 | 百时美施贵宝公司 | 作为rock抑制剂的三唑酮类化合物和四唑酮类化合物 |
CN110049977B (zh) | 2016-07-07 | 2022-01-18 | 百时美施贵宝公司 | 作为强效和选择性rock抑制剂的内酰胺、环状脲和氨基甲酸酯及三唑酮衍生物 |
EP3481828B1 (en) | 2016-07-07 | 2020-09-16 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
WO2018102325A1 (en) | 2016-11-30 | 2018-06-07 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
US11306081B2 (en) | 2017-07-12 | 2022-04-19 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
US11447487B2 (en) | 2017-07-12 | 2022-09-20 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
ES2894128T3 (es) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca |
TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
ES2937039T3 (es) * | 2017-11-03 | 2023-03-23 | Bristol Myers Squibb Co | Inhibidores diazaespiro de ROCK |
BR112021006488A2 (pt) | 2018-10-05 | 2021-07-06 | Annapurna Bio Inc | compostos e composições para o tratamento de condições associadas com atividade do receptor apj |
MX2021005273A (es) | 2018-11-06 | 2021-09-08 | Cervello Therapeutics LLC | Inhibidores de quinasa rock. |
US11248004B2 (en) | 2018-11-06 | 2022-02-15 | Cervello Therapeutics, Llc. | Substituted isoquinolines as rock kinase inhibitors |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE267011T1 (de) | 1995-12-21 | 2004-06-15 | Bristol Myers Squibb Pharma Co | Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren |
ES2228267B1 (es) | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
ES2232292B1 (es) | 2003-07-30 | 2006-11-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos. |
JP2007519754A (ja) | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
US8575167B2 (en) | 2007-02-06 | 2013-11-05 | Takeda Pharmaceutical Company Limited | Spiro compounds having stearoyl-CoA desaturase action |
WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
ES2684776T3 (es) | 2013-01-18 | 2018-10-04 | Bristol-Myers Squibb Company | Ftalazinonas e isoquinolinonas como inhibidores de ROCK |
CN105102448B (zh) * | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
AR094929A1 (es) * | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效rock抑制劑的三環甲醯胺衍生物 |
US9663529B2 (en) | 2013-07-02 | 2017-05-30 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
US10112939B2 (en) | 2014-08-21 | 2018-10-30 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
WO2016065582A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
JP6779214B2 (ja) | 2015-01-09 | 2020-11-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての環状ウレア |
EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
CN109153663B (zh) | 2016-05-27 | 2021-08-13 | 百时美施贵宝公司 | 作为rock抑制剂的三唑酮类化合物和四唑酮类化合物 |
EP3481828B1 (en) | 2016-07-07 | 2020-09-16 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
CN110049977B (zh) | 2016-07-07 | 2022-01-18 | 百时美施贵宝公司 | 作为强效和选择性rock抑制剂的内酰胺、环状脲和氨基甲酸酯及三唑酮衍生物 |
WO2018102325A1 (en) | 2016-11-30 | 2018-06-07 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
US11306081B2 (en) | 2017-07-12 | 2022-04-19 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
ES2894128T3 (es) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca |
US11447487B2 (en) | 2017-07-12 | 2022-09-20 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
ES2937039T3 (es) | 2017-11-03 | 2023-03-23 | Bristol Myers Squibb Co | Inhibidores diazaespiro de ROCK |
-
2017
- 2017-07-06 KR KR1020197003127A patent/KR102491994B1/ko active IP Right Grant
- 2017-07-06 WO PCT/US2017/040850 patent/WO2018009625A1/en unknown
- 2017-07-06 JP JP2019500399A patent/JP7113810B2/ja active Active
- 2017-07-06 ES ES17740241T patent/ES2821877T3/es active Active
- 2017-07-06 EP EP17740241.9A patent/EP3481817B1/en active Active
- 2017-07-06 CN CN201780054599.9A patent/CN109689639B/zh active Active
- 2017-07-06 US US16/315,678 patent/US10696674B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6613306B2 (ja) | アルドステロン合成酵素阻害剤としてのスピロジアミン誘導体 | |
AU2010331175B2 (en) | Novel antiplatelet agent | |
JPWO2018009625A5 (pt) | ||
RU2497813C2 (ru) | 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение | |
WO2020201991A1 (en) | Protein tyrosine phosphatase inhibitors | |
KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
KR20150036142A (ko) | 신장 외수질 칼륨 채널의 억제제로서 사용하기 위한 스피로 - 융합된 피페리딘 유도체 | |
WO2020047208A1 (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
KR20150041787A (ko) | 2,3-벤조디아제핀 | |
JP2010504352A5 (pt) | ||
WO2016065236A1 (en) | Carbazole derivatives | |
KR20160022889A (ko) | 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물 | |
EA001374B1 (ru) | Производные 1-(1,2-дизамещенный пиперидинил)-4-(конденсированный имидазол)-пиперидина | |
KR20180016485A (ko) | 무스카린성 m2 수용체의 양성 알로스테릭 조정제 | |
KR20220129554A (ko) | Enl/af9 yeats의 억제제 | |
JP2020523331A (ja) | アリール複素環ピペリジノンホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト | |
JP2019023212A (ja) | 新しい3,4−ジヒドロ−2h−イソキノリン−1−オン及び2,3−ジヒドロ−イソインドール−1−オン化合物 | |
CN109689656B (zh) | 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途 | |
US10906905B2 (en) | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | |
WO2023224894A1 (en) | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
TWI642668B (zh) | 新穎3,4-二氫-2h-異喹啉-1-酮及2,3-二氫異吲哚-1-酮化合物 | |
WO2014055595A1 (en) | Indoline compounds as aldosterone synthase inhibitiors related applications | |
US20030166926A1 (en) | Pyrroloazepine derivatives | |
JPH05262722A (ja) | 置換n−ビフエニリルラクタム類 | |
JP2006525309A (ja) | ピロロ(1,2−b)ピリダジン化合物、ならびにCRF−1受容体拮抗薬としてのその使用 |